Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.

Eleonora CamilleriMira GhobreyalMettine H A Bos Pieter H ReitsmaFelix J M Van Der MeerJesse Joachim Swen Suzanne C Cannegieter Nienke van Rein

Published in: Pharmacotherapy (2024)

CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.

Keyphrases

atrial fibrillation
venous thromboembolism
gene expression
copy number
genome wide
replacement therapy